Impact of Switching to Continuous Release Dopamine Agonists
NCT00465452
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
11
Enrollment
OTHER
Sponsor class
Conditions
Parkinson Disease
Interventions
DRUG:
Continuous Release Dopamine Agonists
Sponsor
University of Toledo